Europe – EU OKs Alzheimer’s blood test from C2N

C2N Diagnostics has been granted CE mark certification for PrecivityAD, a mass spectrometry-based blood test for Alzheimer’s disease.

The diagnostic is now cleared in Europe for evaluating patients being assessed for Alzheimer’s disease who show mild cognitive impairment or very mild dementia. C2N said its researchers found the test is able to predict Alzheimer’s disease brain pathology in people aged 60 and up with cognitive impairment…